Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$279.59 USD

279.59
189,695

-1.43 (-0.51%)

Updated Apr 19, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

New Strong Sell Stocks for April 19th

by Zacks Equity Research

ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

by Zacks Equity Research

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Waters (WAT) Boosts Waters Operating Segment With HPLC System

by Zacks Equity Research

Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.

Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?

by Zacks Equity Research

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

by Zacks Equity Research

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 5.80% and 0.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Riya Anand headshot

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024

by Riya Anand

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

by Zacks Equity Research

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for On Bio-Rad Laboratories (BIO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of -18.82% and 8.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More

by Urmimala Biswas

Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Bio-Rad (BIO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bio-Rad (BIO) stock based on the movements in the options market lately.

ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?

by Zacks Equity Research

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

New Strong Sell Stocks for September 19th

by Zacks Equity Research

BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.

New Strong Sell Stocks for August 18th

by Zacks Equity Research

BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.